Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT)

Research analysts at Lake Street Capital assumed coverage on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $4.00 price target on the stock.

Several other equities research analysts have also issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday, March 25th. Stifel Nicolaus reduced their target price on shares of Bolt Biotherapeutics from $1.25 to $1.00 and set a “hold” rating for the company in a research report on Tuesday, May 13th.

Bolt Biotherapeutics Stock Performance

Bolt Biotherapeutics stock traded down $0.00 during mid-day trading on Tuesday, reaching $0.33. 20,352 shares of the company traded hands, compared to its average volume of 154,907. The firm’s fifty day moving average is $0.37 and its two-hundred day moving average is $0.48. Bolt Biotherapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $0.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The company has a market capitalization of $12.50 million, a price-to-earnings ratio of -0.19 and a beta of 0.96.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Monday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. The firm had revenue of $1.22 million during the quarter, compared to analysts’ expectations of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. On average, equities research analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter worth $25,000. Squarepoint Ops LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $26,000. Velan Capital Investment Management LP acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at $27,000. Finally, Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at $42,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.